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Summary Agents capable of reversing P-glycoprotein-associated multidrug resistance have usually failed to enhance chemotherapy activity
in patients with solid tumours. Based on its toxicity profile and experimental potency, dexverapamil, the R-enantiomer of verapamil, is
considered to be promising for clinical use as a chemosensitizer. The purpose of this early phase 11 trial was to evaluate the effects of
dexverapamil on epirubicin toxicity, activity and pharmacokinetics in patients with metastatic breast cancer. A two-stage design was applied.
Patients first received epirubicin alone at 120 mg m-2 i.v. over 15 min, repeated every 21 days. Patients with refractory disease continued to
receive epirubicin at the same dose and schedule but supplemented with oral dexverapamil 300 mg every 6 h x 13 doses. The Gehan design
was applied to the dexverapamil/epirubicin cohort of patients. Thirty-nine patients were entered on study, 25 proceeded to receive epirubicin
plus dexverapamil. Dexverapamil did not increase epirubicin toxicity. The dose intensity of epirubicin was similar when used alone or with
dexverapamil. In nine intrapatient comparisons, the area under the plasma concentration-time curve (AUC) of epirubicin was significantly
reduced by dexverapamil (mean 2968 vs 1901 gg ml-1 h-1, P= 0.02). The mean trough plasma levels ofdexverapamil and its major metabolite
nor-dexverapamil were 1.2 and 1.5gM respectively. The addition of dexverapamil to epirubicin induced partial responses in 4 of 23 patients
evaluable for tumour response (17%, Cl 5-39%, s.e.,p 0.079). The remissions lasted 3, 8, 11 and 11+ months. These data suggest that the
concept of enhancing chemotherapy activity by adding chemosensitizers may function not only in haematological malignancies but also in
selected solid tumours. An increase in the AUC and toxicity of cytotoxic agents does not seem to be a prerequisite for chemosensitizers to
enhance anti-tumour activity.
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The concept of overcoming P-glycoprotein (P-gp)-associated
multidrug resistance (MDR) in cancer has received much attention
in recent years. P-gp is a 170-kDa transmembrane protein that
functions as an energy-dependent multidrug efflux pump
(Gottesman and Pastan, 1993). Many ofthe cytotoxic agents used
in the clinical treatment ofbreast cancer are affected by P-gp-asso-
ciated MDR, e.g. anthracyclines, Taxus compounds, mitoxantrone
and Vinca alkaloids. Overexpression of MDR1I/P-gp has been
detected in a variety of human cancers (Goldstein et al, 1989;
Goldstein, 1996; Marie et al, 1996). In tumour types such as acute
myeloid leukaemia, various childhood cancers, advanced primary
breast cancer and high-grade osteosarcomas, MDR1/R-gp over-
expression has been associated with poor treatment outcome
(Chan et al, 1990, 1991; Pirker et al, 1991; Verelle et al, 1991;
Baldini et al, 1995). It is currently unclear whether this is due to
P-gp-mediated cellular resistance or because P-gp expression is in
some way indicative of a more malignant phenotype (Pinedo and
Giaccone, 1995; Lehnert, 1996). Nonetheless, this type ofdata has
raised hope that effective clinical circumvention of P-gp-associ-
ated MDR may improve chemotherapy results.
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A variety ofcompounds has proved to be capable ofreversing
MDR in preclinical tumour models (Ford, 1996). The main
mechanism through which these so-called chemosensitizers are
thought to function is competitive inhibition of the binding of
cytotoxic drugs to P-gp. As a result, P-gp-mediated efflux of
cytotoxic agents is inhibited, leading to increased intracellular
drug accumulation and thus cytotoxicity. A number of clinical
studies has been conducted to evaluate the effects ofchemosensi-
tizers on clinical chemotherapy resistance (Sikic, 1993; Ferry et
al, 1996; Sonneveld, 1996). In multiple myeloma, verapamil and
cyclosporin A have proved capable of overcoming resistance in
patients refractory to treatment with VAD [vincristine,
Adriamycin (doxorubicin) dexamethasone] (Salmon et al, 1991;
Sonneveld et al, 1992). In malignant lymphomas and acute
myeloid leukaemias, data have accumulated that suggest supple-
menting chemotherapy with verapamil or cyclosporin A to be
able to potentiate chemotherapy activity (Miller et al, 1991; List
et al, 1993). In the many studies conducted in solid tumours,
chemosensitizers have usually failed to enhance chemotherapy
activity (Ferry et al, 1996). Only a few of these trials have been
designed in a fashion that allows unequivocal assessment of
chemosensitizer activity. In a prospective randomized trial in
advanced non-small-cell lung cancer, oral verapamil has been
found to increase the response rate to vindesine-containing
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chemotherapy and to significantly prolong survival (Millward et
al, 1993). In two randomized trials in metastatic breast cancer,
quinidine and verapamil were not able to enhance epirubicin
activity (Mross et al, 1993a; Wishart et al, 1994). Various studies
have evaluated the effects of chemosensitizers on the pharmaco-
kinetics and toxicity of cytotoxic agents (Kerr et al, 1986; Bisset
etal, 1991; Lum etal, 1992; Philip et al, 1992; Mross etal, 1993b;
Scheithauer et al, 1993; Bartlett et al, 1994; Berg et al, 1995;
Motzer et al, 1995; Wilson et al, 1995a; Boote et al, 1996). The
data from these studies have suggested that an increase in the area
under the plasma concentration-time curve (AUC) and toxicity of
cytotoxic drugs by chemosensitizers may be indicative ofhaving
achieved chemosensitizer concentrations that are high enough to
effectively inhibit P-gp function (Fisher et al, 1996).
In clinical studies with verapamil, the cardiac effects of this
calcium-channel blocker have limited dose escalation and thus the
plasma levels have usually remained well below the concentrations
needed for effective P-gp inhibition (Ozols et al, 1987; Pennock et
al, 1991). The formulation of verapamil used in those studies has
been a racemic mixture of R- and S-verapamil. R-verapamil has
been reported to have cardiac activity that is five- to ten-fold lower
than that produced by S-verapamil (Echizen et al, 1985), whereas
the two isomers have shown similar molar potency in reversing
P-gp-associated MDR (Gruber et al, 1988; Pirker et al, 1990).
These observations have led to the clinical development ofdexver-
apamil, the R-enantiomer of verapamil, for reversal of MDR in
cancer patients. The objectives of the present early phase II trial in
patients with metastatic breast cancerwere to evaluate the effects of
dexverapamil on the toxicity ofepirubicin, its ability to overcome
epirubicin refractoriness and its effects on the pharmacokinetics of
epirubicin and its metabolism. The present article focuses on the
effects of dexverapamil on epirubicin toxicity and anti-tumour
activity. Furthermore, the effects of dexverapamil on the AUC of
epirubicin and the trough plasma levels achieved by dexverapamil
and its major metabolite nor-dexverapamil are reported. Detailed
data on the dexverapamil effects on the pharmacokinetics ofepiru-
bicin and seven ofits metabolites will be communicated separately
(K Mross et al, manuscript in preparation).
PATIENTS AND METHODS
Thirty-nine women with metastatic breast cancer were entered on
trial. Eligibility criteria included: histologically or cytologically
proven breast cancer; age of 18-65 years; measurable, progressive
metastatic disease; adequate bone marrow, liver and renal func-
tion; no significant cardiac disease; resting systolic blood pressure
2 100 mmHg; heart rate .50 min-'; no concomitant treatment with
cardiac or antihypertensive agents or with agents known to be
capable of reversing P-gp-associated MDR; cumulative doses of
doxorubicin, epirubicin and mitoxantrone lower than 240 mg m-2,
360 mg m-2 and 56 mg m-2, respectively; written informed
consent. The study was approved by the ethical committees of the
participating institutions.
Mandatory baseline studies included: history, physical exami-
nation, determination of performance status and vital signs, body
temperature, complete peripheral blood cell count, including
platelets, blood chemistry, urinalysis, electrocardiogram, echo-
cardiography orradionuclide cardioangiography, chestradiography
and ultrasound of the liver. CAT scans of the liver, abdomen and
chest, bone scan and bone radiographs were obtained if clinically
indicated or ifneeded for bidimensional tumour measurement.
A two-stage design was applied. Patients first received epi-
rubicin alone at 3-week intervals. Patients with refractory disease
proceeded to receive epirubicin at the same dose and schedule but
supplemented with dexverapamil. Refractoriness to epirubicin was
defined as tumour progression, either immediately or after tempo-
rary remission, or a lack of any tumour reduction after two cycles
with epirubicin. Patients with an objective response or any degree
of tumour reduction, however minor, continued to receive epiru-
bicin alone until tumourprogression orreaching atotal cumulative
epirubicin dose of> 1000 mg m-2, whichever occurred first.
Epirubicin was given at 120 mg m-2 as intravenous infusion
over 15 min. The epirubicin dose was reduced by 25% ifany ofthe
following occurred: WBC nadir <1.0 x 1091-'; granulocyte nadir
of <0.9 x 109 1-' if associated with infection; platelet nadir of
<50 x 109 1-1; mucositis of WHO grade .3; mucositis of WHO
grade 2 lasting >7 days. Retreatment with epirubicin was post-
poned for a minimum of 1 week if, on day 21, neutrophils were
<2.0 x 109 1- or platelets <100 x 1091-. Ifblood counts remained
below these limits by day 42, patients were withdrawn from study.
Dexverapamil was given orally at 300 mg every 6 h for a total of
13 doses. Epirubicin was administered after the ninth dose, i.e. 2
days after the start of dexverapamil. The dexverapamil dose was
reduced to 250 mg if any of the following occurred: drop in
systolic blood pressure below 80 mmHg; any drop in systolic
blood pressure associated with clinical symptoms; prolongation of
PQ time of .0.28 s. The dexverapamil dose was escalated to
350 mg if no toxicities were observed to 300 mg. To ensure close
cardiac monitoring, patients on dexverapamil/epirubicin were
hospitalized for the first treatment cycle and for any further cycle
in which the dose ofdexverapamil was modified, i.e. either dimin-
ished or escalated.
Tumour response was evaluated every two cycles. Epirubicin
toxicity was assessed immediately before and on day 12 ± 3 of
each cycle. Patients were withdrawn from study if any of the
following occurred: progressive disease after two cycles or no
change after four cycles with dexverapamillepirubicin; progres-
sion after objective response to dexverapamillepirubicin; total
cumulative dose ofepirubicin of>1000 mg m-2; any organ toxicity
of WHO grade 4, with the exception of alopecia, nausea and
vomiting, drop in WBC and neutrophils without infection, drop in
platelets not associated with life-threatening haemorrhage; any
degree of thrombocytopenia associated with life-threatening
haemorrhage; clinical signs of congestive heart failure or >25%
drop in cardiac ejection fraction; any drop in systolic blood pres-
sure associated with clinical symptoms or PQ prolongation of
.0.28 s in patients receiving dexverapamil at 250 mg; second or
third degree AV block.
The following collateral studies were intended if feasible and
consented to by thepatients: determination oftrough plasma levels
of dexverapamil and nor-dexverapamil; analysis of serum from
patients receiving dexverapamil for the ability to block P-glyco-
protein function ex vivo; analysis of epirubicin pharmacokinetics
and seven of its metabolites when given alone or with dexvera-
pamil; and analysis ofMDR1/P-glycoprotein expression in tumour
biopsies. Dexverapamil plasma levels and ex vivo bioassay
activity were determined in blood samples obtained immediately
before administration ofthe ninth dexverapamil dose, i.e. 6 h after
the preceding dexverapamil dose. Plasma and serum were sepa-
rated and immediately stored at -80'C until analysis. Plasma
concentrations of dexverapamil and nor-dexverapamil were
analysed using apreviously described specific andhighly sensitive
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Table 1 Characteristics of patients proceeding to dexverE
(n= 25)
Age (years)
Median (range) 56 (35-64)
Menopausal status
Premenopausal
Post-menopausal
Disease-free interval
<2 years
.2 years
None
Sites of metastases (mutually non-exclusive)
Liver
Lung
Bone
Lymph nodes
Others
Two sites
> Three sites
Dominant site of disease
Visceral
Bone
Soft tissue
Prior chemotherapy
Adjuvant only
Palliative only
Adjuvant + palliative
Prior anthracyclines
Best response to prior palliative chemotherapy (n = 10)
Complete response
Partial response
No change
Progressive disease
apamil/epirubicin any particular response rate achieved was set as being acceptable.
Tumour response, i.e. complete and partial remission, no change
No. of patients and progressive disease, was assessed according to UICC criteria
(Hayward et al, 1977). Toxicity was graded according to World
Health Organization (WHO) criteria (Milleret al, 1981). Statistical
comparisons oftoxicity data forepirubicin alone vs epirubicin plus
dexverapamil were performed by applying the non-parametric
4 Wilcoxon test forpaired data or the Student's t-test, as appropriate.
21 Data were considered statistically significant if the two-tailed
P-value was <0.05.
10
9
6 RESULTS
15
10
14
10
4
15
10
21
2
2
19
9
7
3
8
2
6
high-performance liquid chromatography method (Harapat and
Kates, 1980). For analysis ofthe P-gp-blocking activity ofdexver-
apamil-containing patient serum, an ex vivo bioassay was used,
which has been previously described (Lehnert et al, 1996).
Epirubicin, epirubicinol, their glucuronides, aglycones and 7-
deoxy-aglycones were quantitated using a high-performance
liquid chromatography (HPLC) method. Details of the HPLC
method and of the analysis of the various pharmacokinetic para-
meters determined in this study, e.g. AUC, volume ofdistribution
at steady state and plasma clearance, have been previously
described (Maessen et al, 1987; Mross et al, 1990, 1993b). The
methods that were to be used for analysis of P-gp and MDR1
mRNA expression in fine-needle tumour biopsies were immuno-
histochemistry and reverse transcriptase-polymerase chain reac-
tion (RT-PCR) respectively. However, the ethical committees
objected to the idea ofsubjecting patients to an invasive procedure
solely for the purpose of analysing MDR1I/P-gp expression, and
the provision had to be installed that tumour biopsies may be
performed only if microscopic proof of tumour recurrence was
clinically required. As it tumed out, no patient met this criterion
and thus data on MDR1/P-gp expression could not be obtained.
The design described by Gehan and Schneiderman was applied
to the dexverapamil/epirubicin cohort of patients (Gehan and
Schneiderman, 1982, pp. 531-553). A response rate of 20% to
dexverapamil/epirubicin with a beta error of 5% was predeter-
mined as the activity level ofinterest. A standard errorof<0.10 for
Thirty-nine patients were entered on trial, 25 proceeded to
receive dexverapamil/epirubicin. Ten patients (one with
complete remission, seven with partial remission and two with
no change) reached the total cumulative epirubicin dose before
progression, two patients had a continuing partial remission after
four cycles of epirubicin at the time the study was closed. Two
patients with metastatic inflammatory breast cancer had early
progression of the primary tumour after one cycle of epirubicin
and were taken off study. The baseline characteristics of the
25 patients proceeding to dexverapamillepirubicin are shown in
Table 1.
Toxicity
Twenty-four patients were evaluable for toxicity, 23 for epirubicin
toxicity without vs with dexverapamil. One patient with tumour
progression was withdrawn from study before the first dexvera-
pamil/epirubicin cycle because, in the last cycle of epirubicin
alone, leucocytopenia of WHO grade 4 developed without
recovery for >3 weeks. One patient received dexverapamil but not
epirubicin, because she developed serious cardiac toxicity afterthe
fourth dose of dexverapamil in the first cycle and refused further
study treatment. A total of58 and 82 cycles ofepirubicin alone and
dexverapamil/epirubicin, respectively, were administered in the 24
patients evaluable for toxicity; the median number ofcycles given
per patient was two (range one to six) and four (range one to six)
respectively. No statistically significant difference was found
between the two treatment groups in non-cardiac toxicities
(Table 2). The haemoglobin nadirs were lower in the patients
receiving dexverapamil/epirubicin (means 96 vs 105 g 1-',
P = 0.002). The mean WBC, neutrophil and platelet nadirs in
patients treated with epirubicin alone or combined with dexvera-
pamil were 2.03 vs 2.05, 0.96 vs 1.21 and 158 vs 143 (x 109 l-l),
respectively, and were not significantly different statistically.
Comparative toxicities were similar when analysed for all treat-
ment cycles or the head-to-head cycles ofepirubicin alone and in
combination with dexverapamil (data not shown). Epirubicin dose
intensity was 34.4 and 35.5 mg m-2 week-', respectively, when
used without and with dexverapamil. Adverse cardiac effects were
more severe in patients receiving dexverapamil/epirubicin
(Table 3). Eight, four and 11 patients on dexverapamil/epirubicin
experienced a heart rate of <60 min-', a drop in systolic blood
pressure to <80 mmHg, and a first-degree AV block respectively.
Usually, the cardiovascular effects remained clinically asympto-
matic and were rapidly reversible upon termination of dexvera-
pamil. In the 20 patients who received more than one cycle of
dexverapamil/epirubicin, dexverapamil dose was escalated in
eight and reduced in four patients.
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Table 2 Non-cardiac toxicity according to worst episodes per patient
Epirubicin alone Epirubicin + dexverapamil
No.a Ob 1 2 3 4 0 1 2 3 4
WBC 20 1 2 6 7 4 1 2 5 10 2
Neutrophils 10 1 0 3 3 3 1 0 2 5 2
Platelets 19 14 3 2 0 0 13 3 0 2 1
Haemoglobin 20 6 9 5 0 0 2 9 9 0 0
Infection 23 21 2 0 0 0 21 0 1 1 0
Bleeding 23 21 1 1 0 0 23 0 0 0 0
Mucositis 23 17 3 3 0 0 12 6 5 0 0
Nausea 23 6 12 5 0 0 4 12 5 2 0
Vomiting 23 13 4 4 2 0 14 2 6 1 0
aNumber of patients with available paired data. bGrading according to WHO criteria.
Table 3 Adverse cardiac effects (n = 24)
Epirubicin Epirubicin
alone +dexverapamil P-valuea
Heartrate(1 permin) 82±Job 73±7 <0.01
Blood pressure (mmHg)
Systolic 133 ± 13 108 ± 15 < 0.01
Diastolic 83 ± 6 67 +8 < 0.01
PQ time (ms) 160 ± 17 187 ± 25 < 0.01
aCalculated by Student's t-test. bValues represent mean ± s.d. of worst
episodes per patient.
Three serious adverse events were recorded in the patients
receiving dexverapamil/epirubicin. A 51-year-old patient died
during the fourth dexverapamil/epirubicin treatment. The initial
three cycles ofdexverapamil/epirubicin were well tolerated. In the
fourth cycle, 11 dexverapamil doses and epirubicin were adminis-
tered according to schedule. Because of nausea the patient refused
to take the 12th dexverapamil dose. At that time, the ECG was
normal, the heart rate was 80 (1 per min), the blood pressure
120/80 (mmHg), and there were no clinical signs of congestive
heart failure. Two hours later, the patient was found dead beside
her bed. The autopsy showed a dilated left cardiac ventricle,
moderate haemostasis and oedema in the lungs, and acute
haemcstasis in liver, spleen and kidneys. Evidence for thrombo-
embolism or myocardial ischaemia was not found. In one patient,
the fourth dexverapamil dose of the first cycle was followed by a
drop in systolic blood pressure from 110 to 60 mmHg. The ECG
showed a PQ time of0.32 s, the heart rate was normal. The patient
was asymptomatic and after cessation of DPVM, blood pressure
and PQ time returned to normal. Further study treatment was
refused by the patient. In one patient, WHO grade 4 elevation of
liver enzymes was observed. The patient had no liver metastases
and liver enzymes were normal at baseline and in the first two
dexverapamil/epirubicin cycles. At the time of the third cycle, the
patient had been taking oral erythromycin for 5 days at a daily
dose of 1 g. After the seventh dose of 300 mg dexverapamil, a
>tenfold increase of ALAT and ASAT was recorded along with a
>fivefold increase in y-GT and LDH. Subjective symptoms were
absent. Treatment with dexverapamil and erythromycin was
discontinued and 2 weeks later the liver enzymes had returned to
normal. Because it was unclear whether the liver toxicity had
been caused by dexverapamil or erythromycin, dexverapamil
Table 4 Tumour response
Epirubicin Epirubicin DexverapamiV
alonea aloneb epirubicin
(n = 39) (n = 25) (n = 23)
Complete response 1 0 0
Partial response 12 3 4
Nochange 18 16 15
Progressive disease 8 6 4
Response rate
Per cent 33 12 17
95% Cl 5-39
s.e.pc 0.079
aAll patients treatedwit[i epirubicin. bPatients proceeding to
dexverapamil/epirubicin. cs.e.p, standard error of probability.
administration was resumed after normalization of liver enzymes.
After the seventh dexverapamil dose, liver enzymes again
increased by >tenfold and returned to normal after cessation of
therapy. The patient was withdrawn frpm study, and liver enzymes
have continued to be in the normal range for 14+ months.
Tumour response
Tumour response to epirubicin alone and dexverapamillepirubicin
is shown in Table 4. All patients with an objective response to
epirubicin alone showed clear signs of tumour reduction after two
treatment cycles. Among the initial 14 patients evaluable for
tumour response to dexverapamilVepirubicin, three achieved a
partial remission. Thus, patient accrual continued. Of the 25
patients proceeding to dexverapamillepirubicin, two were not
evaluable for response because, for the reasons described above,
they never received epirubicin in combination with dexverapamil.
In 4 out of23 patients (17%, 95% Cl 5-39%, s.e.p 0.079), the addi-
tion of dexverapamil induced a partial response to epirubicin
lasting 3, 8, 11 and 11+ months. Three of the responders had liver
metastases as the dominant site of disease, one had mediastinal
lymph node metastases. Two had previously received anthracy-
clines (adjuvant therapy with doxorubicin/vincristine and pallia-
tive treatment with epirubicin/cyclosphosphamide), one patient
had received adjuvant CMF and one was not pretreated with
chemotherapy. In all of the four patients, the reason for adding
dexverapamil was lack of any tumour reduction after two cycles
with epirubicin alone. The objective remissions to dexverapa-
mil/epirubicin were recorded after two further cycles with the
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Figure 1 Plasma concentration-time curves of epirubicin (EPI) when used
alone or in combination with dexverapamil (DVPM) in three patients [KW (A),
KA (B), LeE (C)] with objective remission to dexverapamil/epirubicin. The first
data points plotted are the plasma levels measured at the end of the
epirubicin infusion. In each patient, the epirubicin dose given without and with
dexverapamil was 120 mg m-2. The absolute doses of epirubicin administered
in patients K-W, K-A and Le-E were 220, 200 and 250 mg respectively
combination. An additional patient who was progressing after two
cycles with epirubicin alone had a 45% reduction in the size ofher
liver metastases after two cycles with dexverapamillepirubicin. A
further response assessment was not performed because this was
the particular patient who died during the fourth treatment cycle
with the combination (see above).
Data from collateral studies
In nine patients, epirubicin pharmacokinetics was determined
without and with dexverapamil. When given alone and combined
with dexverapamil, the epirubicin AUC (mean ± s.e.m.) was
2968 ± 1219 ,ug ml-' h-' and 1901 ± 494 jg ml-1 h-1 respectively
(P = 0.02). Dexverapamil treatment reduced the epirubicin AUC
in eight out of nine patients and had no effect in one patient.
The mean reduction of epirubicin AUC was 36%. In three out of
four patients responding to dexverapamil/epirubicin, data on
epirubicin pharmacokinetics are available from the first cycles
with epirubicin alone and with dexverapamil. In two of these
patients, dexverapamil diminished the AUC of epirubicin, in one
patient dexverapamil had no effect on the epirubicin plasma
concentration-time curve (Figure 1). The mean trough plasma
levels of dexverapamil and nor-dexverapamil, respectively, were
1.2 (range 0.4-3.0) gM and 1.5 (range 0.9-2.6) gM. If the concen-
tration of the parent compound was <2.0 gM, which was the case
in 31 out of 37 analyses (83%), the ratio of nor-dexverapamil to
dexverapamil was always >1 (mean 1.56, range 1.1-2.2). The
opposite was true in the six samples with dexverapamil concen-
trations of >2.0gM. All 16 serum samples analysed from patients
receiving dexverapamil were found capable ofinhibiting P-glyco-
protein-mediated efflux ex vivo, and a good correlation was found
between dexverapamil plasma levels and bioassay activity
(Lehnert et al, 1996).
DISCUSSION
Dexverapamil is one of the second-generation chemosensitizers
that have been specifically developed in recent years for clinical
reversal of P-gp-associated MDR. Recently, dexverapamil has
been found capable ofinducing objective remissions to EPOCH, a
combination ofetoposide, prednisolone, vincristine, cyclophospha-
mide and doxorubicin, in 12% of41 patients with non-Hodgkin's
lymphomas refractory to EPOCH alone (Wilson et al, 1995b). In
patients with renal cell carcinoma refractory to vinblastine,
dexverapamil was unable to enhance vinblastine activity (Motzer
et al, 1995). For phase II studies, daily dexverapamil doses of
800 mg total and 900 mg m-2 have been recommended when used
in combination with doxorubicin (Bisset et al, 1991) and EPOCH
(Wilson et al, 1995a) respectively.
In the present study, supplementing epirubicin with dexvera-
pamil was found capable ofinducing partial remissions in 4 out of
23 patients with metastatic breast cancer refractory to the same
dose and schedule ofepirubicin alone. The remissions lasted 3, 8,
11 and 11+ months. An additional patient, with progressive disease
after two cycles with epirubicin, had a45% reduction in the size of
her liver metastases after two more cycles with the combination.
The criterion for adding dexverapamil in the four patients with an
objective remission was not tumour progression but rather lack of
any sign of tumour reduction after two cycles with epirubicin. It
may be argued that some of these patients might have gone
into remission by merely continuing treatment with epirubicin
alone. However, in metastatic breast cancer, epirubicin-based
chemotherapy has been found to usually induce responses either
quickly, i.e. within two treatmentcycles, or not at all (Marschner et
al, 1994; Hausmaninger et al, 1995). This is particularly true when
using epirubicin at doses as high as 120 mg m-2. In fact, at the
institutions participating in this study, routine treatment with
epirubicin at this dose would have been stopped in patients with
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metastatic breast cancer if no tumour reduction had been achieved
after two cycles. For these reasons, the lack of any tumour reduc-
tion after two epirubicin cycles was deemed to be a proper crite-
rion for adding dexverapamil in this study. The rapid onset of
response to epirubicin in metastatic breast cancer was confirmed in
the present study. All patients who eventually achieved an objec-
tive remission to epirubicin alone showed clear signs of tumour
reduction after two cycles. Furthermore, in the four patients with
an objective remission to dexverapamil/epirubicin, the response
was apparent after two further cycles with the combination. Taken
together, it seems likely that the objective remissions produced by
dexverapamil/epirubicin were indeed induced by the addition of
dexverapamil and would not have been achieved by longer treat-
ment with epirubicin alone. Obviously, however, the latter possi-
bility cannot be ruled out with certainty.
Recently, two studies in patients with metastatic breast cancer
have been published that prospectively compared epirubicin alone
with epirubicin plus quinidine and racemic verapamil (Mross et
al, 1993a; Wishart et al, 1994). In neither study did the chemosen-
sitizer have an effect on response rate, progression-free or overall
survival. In a two-stage phase II study of bepridil in advanced
solid tumours, two out of five patients with metastatic breast
cancer progressing to anthracyclines had a short-lasting minor
response when bepridil was added (Van Kalken et al, 1991). In a
recently reported study, 1 out of 16 patients with metastatic breast
cancer refractory to vinblastine alone had a partial response upon
the addition of trifluoperazine (Murren et al, 1996). Other
chemosensitizer studies in metastatic breast cancer were not
designed in a manner that allows assessment of chemosensitizer
activity (Ries and Dicato, 1991; Budd et al, 1993; Bates et al,
1995). The dose of epirubicin and its response rate in the present
study were similar to the negative randomized trials of quinidine
and racemic verapamil (Mross et al, 1993a; Wishart et al, 1994).
In the verapamil study, the average steady-state plasma levels
measured for verapamil and nor-verapamil were 265 ng ml-1 and
180 ng ml-1 respectively (Mross et al, 1993b). These concentra-
tions seem to be too low for effective MDR reversal. However,
the median plasma level yielded by quinidine was 5.5 gM
(Wishart et al, 1994), a concentration that has been shown to
reverse MDR in breast cancercells in vitro and to result in tumour
tissue levels of quinidine that are adequate for MDR reversal
(Wishart et al, 1992). Hence, quinidine should have been able to
enhance epirubicin activity similar to dexverapamil in the present
study. However, the task for a chemosensitizer to demonstrate
activity in a randomized trial seems much more difficult than
doing so in a two-stage study in which each patient receiving the
agent is known to be refractory to the particular chemotherapy
and is serving as her/his own control. When we look at the present
data from the perspective of a randomized study, dexverapamil
showed activity in 4 of the 39 patients entered on trial, i.e. in
roughly 10% of the total study population. At the observed
response rate of 33% for epirubicin alone, 389 patients per treat-
ment group would be needed in a randomized study for dexvera-
pamil to demonstrate a 10% increase in the response rate with an
alpha error of 0.05 and a beta error of 0.20. If a clinically more
relevant 20% improvement in the response rate was targeted, as
was the case in the quinidine trial (Wishart et al, 1994), 105
patients would be needed per treatment group. However, a 10%
increase in the response rate by dexverapamil would be missed in
such a trial. Obviously, it can be debated whether missing an
activity level of 10% is good or bad in this particular scenario.
But it might be one reason why quinidine failed to increase the
response rate to epirubicin.
The combination ofdexverapamil and epirubicin was well toler-
ated by most patients. The precise role that dexverapamil/epiru-
bicin played in the one fatal event is not clear, but a relationship
cannot be ruled out with certainty. The patient had tolerated the
three prior cycles with dexverapamillepirubicin without any
adverse cardio-circulatory effects, and ECG, physical examination
and blood pressure were normal 2 h before death when the patient
complained of nausea. Clinically, pulmonary embolism seemed
the most likely cause of death, but this was not evidenced in the
autopsy. The severe liver toxicity observed in another patient
seems to be definitely related to dexverapamil. For racemic vera-
pamil, the same type ofliver injury has been previously described,
and the underlying mechanism may be a hypersensitivity reaction
(Brodsky et al, 1981; Nash and Drumheller Feer, 1983). The
increase in liver enzymes was fully reversible upon withdrawal of
dexverapamil but necessitated cessation oftreatment.
Dexverapamil did not increase the dose-limiting epirubicin toxi-
cities, i.e. on the bone marrow and mucosa. Accordingly, epiru-
bicin could be given at a similar dose intensity without and with
dexverapamil. The mechanism underlying the slightly, albeit
significantly, lower haemoglobin nadirs in the dexverapamill
epirubicin cohort of patients is unclear. The differences in haemo-
globin nadirs were similar when comparing the head-to-head or
all treatment cycles without and with dexverapamil. Thus, the
observed decrease in haemoglobin nadirs was not aresult ofcumu-
lative RBC toxicity by epirubicin. Verapamil itself is not known
to produce RBC toxicity. Therefore, dexverapamil may have
enhanced epirubicin toxicity on RBCs in some yet undefined way.
EDexverapamil significantly diminished the AUC of epiru-
bicin, on average by 36%. This finding is consistent with previ-
ously reported data on the effect of dexverapamil on epirubicin
AUC (Scheithauer et al, 1993) but is in contrast to the pattern
of pharmacokinetic interaction usually observed between
chemosensitizers and cytotoxic agents (Fisher et al, 1996).
Dexverapamil significantly increased the volume of epirubicin
distribution at steady state and the AUC of the non-toxic
metabolites epirubicin-glucoronide and the 7-deoxy-aglycones
(K Mross, personal communication). The mechanisms under-
lying these pharmacokinetic effects are not clear. It may be
speculated that dexverapamil did alter tissue perfusion by virtue
of its peripheral vascular activity. Furthermore, there may be
direct interference by dexverapamil with particular steps in the
hepatic metabolism of epirubicin. The anthracyclines doxoru-
bicin and epirubicin appear to differ with respect to the type of
pharmacokinetic interaction with verapamil. Oral dexverapamil
has been recently reported to increase the steady-state concen-
tration of doxorubicin by 50% (Wilson et al, 1995a). Similarly,
racemic verapamil has been found to increase the peak plasma
levels and terminal half-life of doxorubicin (Kerr et al, 1986),
whereas it has shown no effect on epirubicin AUC (Mross et al,
1993b). Recently, oral dexverapamil has been found to increase
the AUC ofpaclitaxel twofold (Berg et al, 1995), while it had no
effect on the steady-state concentration of etoposide (Wilson et
al, 1995a). With cyclosporin A and its analogue PSC 833, an
increase in AUC and toxicity has been a consistent finding with
any ofthe cytotoxic drugs tested so far (Lum et al, 1992; Bartlett
et al, 1994; Boote et al, 1996). In contrast, the effects of other
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chemosensitizers on the pharmacokinetics and -dynamics of
cytotoxic drugs appear to depend on the particular agents used
in combination.
Verapamil and nor-verapamil have been previously found to be
equipotent in reversing drug resistance in vitro (Merry et al, 1989).
In the present study, the mean trough levels of dexverapamil and
nor-dexverapamil combined were 2.7 gM, a concentration that is
capable of reversing P-gp-associated MDR in experimental
models. In our analyses of ex vivo P-gp-inhibitory activity, each
serum sample from patients receiving dexverapamil proved
capable of inhibiting P-gp function, with good statistical correla-
tion between dexverapamil plasma levels and functional activity
(Lehnert et al, 1996b). In the few plasma samples with dexvera-
pamil levels of> 2.0gM, the ratio ofnor-dexverapamil to dexvera-
pamil was <1, whereas the reverse was true in the 83% ofsamples
with dexverapamil concentrations of <2.0gM. This corroborates
previous observations that the conversion ofdexverapamil to nor-
dexverapamil is a saturable process (Wilson et al, 1995a). Higher
relative plasma concentrations ofnor-dexverapamil have also been
found in other clinical studies of dexverapamil (Scheithauer et al,
1993; Motzer et al, 1995) whereas, with racemic verapamil, the
verapamil to norverapamil ratio has usually been . 1 (Pennock et
al, 1991; Mross et al, 1993b). Norverapamil is known to have only
20% of the cardiovascular activity of the parent compound, when
using the racemic mixture of verapamil (Neugebauer, 1978). R-
verapamil has been shown to have a five- to tenfold lower cardiac
activity than does the S-enantiomer (Echizen et al, 1985), and thus
nor-dexverapamil can be speculated to almost lack cardiac effects.
Accordingly, a nor-dexverapamil to dexverapamil ratio of> 1 may
be associated with diminished cardiac toxicity, without sacrificing
MDR reversing potency.
For ethical reasons, we were not able to perform tumour biop-
sies for analysis of MDRl/P-gp expression. On theoretical
grounds, such information appears to be important in chemosensi-
tizer studies because, in the absence offunctional P-gp expression,
P-gp-inhibitors are not expected to overcome resistance at the
cellular level. In a meta-analysis of all the original studies of
MDRl/P-gp detection in clinical breast cancers, the proportion of
MDRI/P-gp-positive tumours was around 40% (Trock et al,
1997). The results, however, have been highly variable (Goldstein
et al, 1989; Merkel et al, 1989; Wishart et al, 1990; Sanfilippo et
al, 1991; Verrelle et al, 1991; Wallner et al, 1991; Bates et al, 1995;
Linn et al, 1995; Murren et al, 1996; Trock et al, 1997). One reason
for the discrepant data seems to be the different sensitivity and
specificity of the various detection methods used in these studies
(Beck et al, 1996; Broxterman et al, 1996). Prior chemotherapy
seems to significantly increase MDRlI/P-gp expression in breast
tumours and a significant association has been found between
MDRI/P-gp positivity after chemotherapy and lack ofresponse to
the particular treatment (Trock et al, 1997). The biological and
therapeutic implications of these data, however, remain to be
determined (Kaye, 1997).
The observed ability of dexverapamil to overcome epirubicin
refractoriness in patients with metastatic breast cancer appears to
be encouraging. However, these data have to be considered as
preliminary and need confirmation in larger studies. In particular,
it remains to be determined in prospective randomized trials
whether the addition of dexverapamil to epirubicin is able to
improve progression-free and overall survival in patients with this
disease. These reservations notwithstanding, the data from this
study appear to contest two widely held notions, i.e. that the
concept of enhancing chemotherapy activity by chemosensitizers
may only function in haematological neoplasms and that an
increase in the AUC and the toxicity of cytotoxic agents is a
prerequisite for chemosensitizers to enhance anti-tumour activity.
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